Co-promotion contract for Comirnaty vaccine approved last month Sales and marketing collaboration following Comirnaty vaccine distribution Expanded promotion cooperation for National Immunization Program (NIP)
var WiderPlanetAdRendererVar = {
type : "script",
passback : '/images/common/pc_view_banner.jpg',
category : "pc_view_banner",
width : "468",
height : "60",
zoneid : "30713",
targetid : "kb_pc_view_ad"
};
The Comirnaty vaccine received approval from the Ministry of Food and Drug Safety (MFDS) on the 29th of last month for the indication of COVID-19 prevention in individuals aged 12 and over. Regardless of previous COVID-19 vaccinations, it is administered as a 0.3mL intramuscular injection once. If previously vaccinated, it should be administered at least three months after the last vaccination date.
Oh Dong-wook, CEO of Pfizer Korea, conveyed, "Pfizer Korea will continue to strive to protect high-risk groups through the stable supply of COVID-19 vaccines and to complete innovations that change patients' lives."
Kim Min-beom
AI-translated with ChatGPT. Provided as is; original Korean text prevails.
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
About Dong-A Ilbo